We hypothesized that EVs may mediate drug sensitivity in heterogeneous lung cancer via the transfer of cargo from EGFR-mutant cells to EGFR wild-type cells, thus contributing to the sensitivity to EGFR-TKIs observed in heterogeneous EGFR-mutant NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.